Global contrast media market is anticipated to grow at a considerable CAGR of 6.5% during the forecast period (2024-2031). The growing demand for contrast media in the diagnosis of several diseases is a key factor driving the global market. The ongoing R&D programs and FDA approvals to identify the potential new applications of contrast media are further aiding the global market growth. For instance, in June 2023, Bayer initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane, an investigational extracellular macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). Gadoquatrane is a highly stable MRI contrast agent featuring high relativity being studied to evaluate the potential of a substantially lower gadolinium (Gd) dose for patients.
Browse the full report description of “Contrast Media Market Size, Share & Trends Analysis Report by Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, and Barium-based Contrast Media), by Procedure (X-Ray/ Computed Tomography, Magnetic Resonance Imaging (MRI), and Ultrasound), by Indication (Cardiovascular Diseases, Oncology, Gastrointestinal Disorders, and Neurological Disorders) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/contrast-media-market
Further, in March 2023, GE HealthCare announced the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention. The macrocyclic, extra-cellular – or general-purpose – manganese-based contrast agent has comparable relativity - the ability of a contrast agent to enhance signal intensity during an MRI scan - and is expected to be diagnostically similar to current gadolinium-based contrast agents (GBCAs).
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Type
o By Procedure
o By Indication
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Bayer AG, Bracco Diagnostic Inc., GE Healthcare, Guerbet Group, and Lantheus Medical Imaging Inc. among others.
Key questions addressed by the report
Global Contrast Media Market Report Segment
By Type
By Procedure
By Indication
Global Contrast Media Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/contrast-media-market